This resource can be further explored for future studies, but already suggests that targeting multicytokine-producing CD4+ T cells can represent a new therapeutic target for NASH patients using, for example, depleting monoclonal antibodies, antibiotics, or probiotic treatments. This evidence concerns the gene CD4 and metabolic dysfunction-associated steatohepatitis.